Peptide-Functionalized Nanoparticles-Encapsulated Cyclin-Dependent Kinases Inhibitor Seliciclib in Transferrin Receptor Overexpressed Cancer Cells
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Peptide-Functionalized Nanoparticles-Encapsulated Cyclin-Dependent Kinases Inhibitor Seliciclib in Transferrin Receptor Overexpressed Cancer Cells
Authors
Keywords
-
Journal
Nanomaterials
Volume 11, Issue 3, Pages 772
Publisher
MDPI AG
Online
2021-03-19
DOI
10.3390/nano11030772
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evaluation of the Hemocompatibility and Anticancer Potential of Poly(ε-Caprolactone) and Poly(3-Hydroxybutyrate) Microcarriers with Encapsulated Chrysin
- (2021) Eleftherios Halevas et al. Pharmaceutics
- Therapeutic Potential of a Cell Penetrating Peptide (CPP, NP1) Mediated siRNA Delivery: Evidence in 3D Spheroids of Colon Cancer Cells
- (2020) Khalsa Al‐Husaini et al. CANADIAN JOURNAL OF CHEMICAL ENGINEERING
- Cell-Penetrating Peptides in Diagnosis and Treatment of Human Diseases: From Preclinical Research to Clinical Application
- (2020) Jing Xie et al. Frontiers in Pharmacology
- Transferrin receptors targeting peptide (T7 peptide) surface-modified sorafenib nanoliposomes enhance the anti-tumor effect in colorectal cancer
- (2020) Shuaiqi Wang et al. PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY
- Nanoparticle-mediated therapeutic compounds delivery to glioblastoma
- (2020) L. Gallego et al. Expert Opinion on Drug Delivery
- Lipid-based nano delivery of Tat-peptide conjugated drug or vaccine–promising therapeutic strategy for SARS-CoV-2 treatment
- (2020) Mohammad Azam Ansari et al. Expert Opinion on Drug Delivery
- Polymeric Nanoparticles-Based Brain Delivery with Improved Therapeutic Efficacy of Ginkgolide B in Parkinson’s Disease
- (2020) Yuying Zhao et al. International Journal of Nanomedicine
- pH-Activatable cell penetrating peptide dimers for potent delivery of anticancer drug to triple-negative breast cancer
- (2020) So Hee Nam et al. JOURNAL OF CONTROLLED RELEASE
- Clinical cancer nanomedicine
- (2019) Joy Wolfram et al. Nano Today
- Insights into maleimide-thiol conjugation chemistry: Conditions for efficient surface functionalization of nanoparticles for receptor targeting
- (2018) Lucía Martínez-Jothar et al. JOURNAL OF CONTROLLED RELEASE
- Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update
- (2018) Solomon Tadesse et al. JOURNAL OF MEDICINAL CHEMISTRY
- T7 Peptide-Functionalized PEG-PLGA Micelles Loaded with Carmustine for Targeting Therapy of Glioma
- (2016) Yunke Bi et al. ACS Applied Materials & Interfaces
- Systemic delivery of siRNA by T7 peptide modified core-shell nanoparticles for targeted therapy of breast cancer
- (2016) Min-Zhi Yu et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Cyclin-Dependent Kinase 2 Promotes Tumor Proliferation and Induces Radio Resistance in Glioblastoma
- (2016) Jia Wang et al. Translational Oncology
- Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression
- (2015) Liu Yang et al. Oncotarget
- Cytotoxic enhancement of hexapeptide-conjugated micelles in EGFR high-expressed cancer cells
- (2014) Wen Jen Lin et al. Expert Opinion on Drug Delivery
- Gadd45a levels in human breast cancer are hormone receptor dependent
- (2013) Jennifer S Tront et al. Journal of Translational Medicine
- Roscovitine sensitizes leukemia and lymphoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis
- (2012) Jan Molinsky et al. LEUKEMIA & LYMPHOMA
- The transferrin receptor and the targeted delivery of therapeutic agents against cancer
- (2011) Tracy R. Daniels et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- Cdk2 is Required for Breast Cancer Mediated by the Low-Molecular-Weight Isoform of Cyclin E
- (2011) S. Akli et al. CANCER RESEARCH
- Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies
- (2010) Christophe Le Tourneau et al. EUROPEAN JOURNAL OF CANCER
- Peptide-Conjugated PAMAM for Targeted Doxorubicin Delivery to Transferrin Receptor Overexpressed Tumors
- (2010) Liang Han et al. MOLECULAR PHARMACEUTICS
- Development of EGFR-Targeted Polymer Blend Nanocarriers for Combination Paclitaxel/Lonidamine Delivery To Treat Multi-Drug Resistance in Human Breast and Ovarian Tumor Cells
- (2010) Lara Milane et al. MOLECULAR PHARMACEUTICS
- Seliciclib in malignancies
- (2009) Ibrahim T Aldoss et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Inhibition of ovarian cancer cell proliferation by a cell cycle inhibitory peptide fused to a thermally responsive polypeptide carrier
- (2009) Iqbal Massodi et al. INTERNATIONAL JOURNAL OF CANCER
- Strong inhibition of replicative DNA synthesis in the developing rat cerebral cortex and glioma cells by roscovitine
- (2009) Juan Sebastian Yakisich et al. INVESTIGATIONAL NEW DRUGS
- Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicinin vivoin a breast cancer xenograft model
- (2008) Maria Virginia C.L. Appleyard et al. INTERNATIONAL JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started